Last week the Maryland life sciences community traveled 650 miles south to Atlanta, to attend the Biotechnology Industry Organization International Convention from May 18 to 21 BIO is the premier annual event in the life sciences industry and has in the past attracted approximately 30,000 attendees from all 50 states and dozens of countries around the world This year BIO felt the effect of the .I Am Biotech: Discover. Share. Discuss.Biotech Roundup: Monday, June 1. Author: ebarboni. HIGHLIGHTING THE IMPORTANCE OF AGRICULTURE – AgWired has a post today about a new awareness campaign called “The Hand That Feeds U.S.” The campaign, which is a project of .
Researchers at UC Santa Barbara have recently demonstrated a breakthrough in the quantum control of photons, the energy quanta of light. This is a significant result in quantum computation, and could eventually have implications in banking, drug design, and other applications. agriculture biotechnology
Scientists are reporting discovery of a potential new alternative to aspirin, ReoPro, and other anti-platelet agents used widely to prevent blood clots in coronary artery disease, heart attack and stroke. Their study, scheduled for the June 23 issue of ACS Nano, a monthly journal, involves particles of silver – 1/50,000th the diameter of a human hair – that are injected into the bloodstream. agriculture biotechnology
Scientists are reporting a potential solution to a problem that limits the human body’s ability to absorb and use medications for heart disease, Type-2 diabetes, cancer and other conditions. It is a “nano-hybrid microcapsule” that enables the stomach to absorb more of these so-called “poorly-soluble” medicines. Their study is scheduled for the June 1 issue of ACS’ Molecular Pharmaceutics, a bi-monthly journal. agriculture biotechnology
GlaxoSmithKline [NYSE: GSK] and Genmab A/S [OMX: GEN] announced that the United States Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 10 to three that the ARZERRA(TM) (ofatumumab) data are reasonably likely to predict clinical benefit for patients with chronic lymphocytic leukemia (CLL) whose disease is refractory to fludarabine and alemtuzumab. Ofatumumab is an investigational treatment. agriculture biotechnology
